07:00 Thu 28 Nov 2019
ValiRx PLC - US Patent Grant re VAL201 & Metastatic Cancer
("
US PATENT GRANT
FOR THE USE OF VAL201 IN THE PREVENTION AND TREATMENT
OF METASTATIC CANCER
Metastatic cancer is classified when the disease spreads beyond the primary tumour to other parts of the body. This spread is known as metastatic disease and in prostate cancer it commonly spreads to the bones and lymph nodes. The main goals for treatment of metastatic cancer are symptom control, slowing or stopping the rate at which the cancer grows, as well as targeting the underlying cancer.
Dr
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
|
Tel: +44 (0) 20 3008 4416 |
Dr |
Tel: +44 (0) 20 3008 4416 |
|
Tel: +44 (0) 7879 458 364 |
|
|
|
Tel: +44 (0) 20 7213 0880 |
|
|
|
Tel: +44 (0) 20 3328 5656
|
|
|
|
Tel: +44 (0) 20 7399 9400 |
Notes for Editors
About
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in
The Company listed on the AIM Market of the
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE